Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

MINOCYCLINE

Tetracycline

ANTI-INFETCTIVE

CURRENT DEVELOPMENT PHASE: MV-HABP, VABP, ABC

preclinicl
phase i
phase ii
phase iii
pre-registration
post-registration

Menarini is developing an innovative intravenous formulation containing the well-established active substance minocycline, an anti-infective belonging to the class of tetracyclines.

The enhanced intravenous formulation may allow the use of Minocycline for the treatment of rare, life-threatening infections caused by difficult-to-treat pathogens. This makes Minocycline particularly suitable for the treatment of Hospital-Acquired Bacterial Pneumonia requiring Mechanical Ventilation (MV-HABP) / Ventilator Associated Bacterial Pneumonia (VABP) or bacteremia due to Acinetobacter baumannii complex (ABC).

THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more